Utah Business recently featured Halia Therapeutics co-founder David Bearss in their Founder Series

Halia Therapeutics Announces Positive Phase 1 Clinical Trial Results for HT-6184 at the 5th Inflammasome Therapeutics Summit

In a recent interview with BioTuesdays, Halia and Co-Founder David Bearss, P.HD., said that the company is “growing to become a leader in targeting the NLRP3 inflammasome through a unique mechanism of action.” Closely-held Halia Therapeutics is developing a broad pipeline of novel therapies that are essential mediators of immune cell signaling with the potential […]

Halia Therapeutics announced the appointment of Dr. Margit M. Janát-Amsbury, MD, Ph.D. as the company’s Chief Medical Officer

HT-6184 is a novel NEK7/NLRP3 inhibitor

Halia Therapeutics presented data today on its NLRP3 inhibitor program at today’s 10th Annual Neurodegenerative Drug Development Summit. 

Halia Therapeutics New Leadership Team